

Analysis of the Ability of Spirochete Species Associated with Relapsing Fever, Avian Borreliosis, and Epizootic Bovine Abortion To Bind Factor H and Cleave C3b

John V. McDowell,¹ Emily Tran,¹ Duncan Hamilton,¹ Jill Wolfgang,²
Kelley Miller,¹ and Richard T. Marconi^{1*}

Department of Microbiology and Immunology, Center for the Study of Biological Complexity,¹ and Division of Infectious Diseases,²
Medical College of Virginia at Virginia Commonwealth University, Richmond, Virginia 23298

Received 6 March 2003/Returned for modification 14 April 2003/Accepted 11 May 2003

Some *Borrelia* species associated with Lyme disease bind the complement-regulatory protein factor H (fH), a process that may aid in immune evasion. In this report we demonstrate that some *Borrelia* species associated with relapsing fever bind fH, but not those associated with avian borreliosis and epizootic bovine abortion. Cell-bound fH was also found to mediate cleavage of exogenously supplied human C3b, demonstrating the biological relevance of fH binding and its possible importance in the pathogenesis of the relapsing-fever spirochetes.

In North America, tick-borne relapsing fever (TBRF) is caused by *Borrelia hermsii*, *Borrelia parkeri*, and *Borrelia turicatae* (4) and transmitted by *Ornithodoros* ticks. Lyme disease (worldwide) is caused by *Borrelia burgdorferi*, *Borrelia afzelii*, and *Borrelia garinii* and is transmitted by *Ixodes* ticks. TBRF is characterized by cyclic spirochetemias, a high-grade relapsing fever, and in some cases neurological involvement (3). Antigenic variation is central to the ability of the relapsing-fever spirochetes (RFS) to survive in the host and thrive in the blood (5, 15). In the closely related Lyme spirochetes, immune evasion is thought to be a multifactorial process. One newly delineated mechanism that may contribute to immune evasion and the maintenance of chronic infection is the binding of the complement regulatory protein factor H (fH) to the cell surface (1, 2, 7, 8, 10, 13). Under normal conditions, fH is a complement regulatory protein that serves as a cofactor for the factor I (fI)-mediated cleavage of C3b, a key component of the complement cascade (6). FHL-1, which is derived from the same gene as fH via alternative splicing of the mRNA, plays a role similar to that of fH (6). By increasing the local concentration of fH at the cell surface, bacteria that bind fH can more efficiently promote the degradation of C3b and thereby decrease the efficiency of complement-mediated killing. A recent comprehensive analysis of fH binding to Lyme disease spirochetes revealed that 100% of *B. burgdorferi*, 83% of *B. afzelii*, and 25% of *B. garinii* isolates tested bind fH (12). The binding of fH by *B. burgdorferi* and *B. afzelii* may aid in evasion of complement attack and thereby facilitate dissemination (1, 2, 7, 8, 10, 13). The general inability of *B. garinii* to bind fH may account for the frequency with which this species has been isolated from the CNS, since in this niche the bacteria would be protected from complement (13). Here we demonstrate that

some RFS species (*B. hermsii* and *B. parkeri*) can bind human fH (hfH) and that bound fH can interact with fI, leading to the cleavage of C3b. Like the neurotropic species *B. garinii*, the potentially neurotropic RFS species *B. turicatae* does not appear to bind fH. These analyses indicate that fH binding is of biological relevance in the pathogenesis of RFS and may influence dissemination and tissue localization.

To determine if the RFS can bind fH and to identify potential fH binding proteins (FHBPs), an affinity ligand binding immunoblot assay was employed as previously described (12, 13). Briefly, whole-cell lysates of each isolate were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted. The immunoblots were incubated with purified hfH (Calbiochem), unbound fH was removed by washing with phosphate-buffered saline (PBS), and goat anti-hfH antiserum (Calbiochem; 1:800 dilution) was added to screen for fH bound to *Borrelia* proteins. Horseradish peroxidase-conjugated rabbit anti-goat immunoglobulin G served as the secondary antibody (Pierce; 1:40,000). Several *B. hermsii* isolates (DAH, HS1, YOR, and MAN) and *B. parkeri* bound fH, while *B. coriaceae* (epizootic bovine abortion), *B. anserina* (avian borreliosis), *B. turicatae*, and the *B. hermsii* isolates CON and FRO did not (Table 1; Fig. 1). All fH binding isolates expressed an FHP of ~19 kDa (FHP19). *B. parkeri* expressed a second, less dominant FHP of ~28 kDa (FHP28). In contrast, the Lyme disease spirochetes produce multiple, variable FHBPs (2, 12). Here we demonstrate differences in fH binding phenotype among RFS species, a feature that may contribute to the different pathogenesis of individual RFS species. Most *B. hermsii* isolates and *B. parkeri* bind fH, while *B. turicatae* does not. *B. hermsii* and *B. parkeri* infections are typically characterized by high bacterial cell densities in the blood and an absence of central nervous system (CNS) invasion. In contrast, *B. turicatae* tends to infect the CNS. Residence in this niche may serve to protect *B. turicatae* from complement. It is important to note that the *B. hermsii* isolates CON and FRO, which were originally recovered from

* Corresponding author. Mailing address: Medical College of Virginia at Virginia Commonwealth University, Microbiology and Immunology, 1112 E. Clay St., McGuire Hall, Room 101, Richmond, VA 23298-0678. Phone: (804) 828-3779. Fax: (804) 828-9946. E-mail: rmarconi@hsc.vcu.edu.

TABLE 1. Description of bacteria used in this study

Isolate	Associated disease	Origin	fH binding
<i>B. hermsii</i> HS1	TBRF	<i>O. hermsii</i> , Washington	+ (FHBP19)
<i>B. hermsii</i> YOR	TBRF	Human blood, California	+ (FHBP19)
<i>B. hermsii</i> CON	TBRF	Human blood, California	-
<i>B. hermsii</i> FRO	TBRF	Human blood, Washington	-
<i>B. hermsii</i> DAH	TBRF	Human blood, Washington	+ (FHBP19)
<i>B. hermsii</i> MAN	TBRF	Human blood, California	+ (FHBP19)
<i>B. parkeri</i> RML	TBRF	<i>Ornithodoros parkeri</i> , origin unknown	+ (FHBP19 and FHBP28)
<i>B. turicatae</i> OZ-1	TBRF	<i>Ornithodoros turicata</i> , Texas	-
<i>B. coriaceae</i> Co53	Epizootic bovine abortion	<i>Ornithodoros coriaceus</i> , California	-
<i>B. anserina</i> BA2	Avian borreliosis	Domestic chicken	-
<i>B. anserina</i> LSP	Avian borreliosis	Domestic chicken	-
<i>B. burgdorferi</i> B31MI	Lyme disease	<i>Ixodes scapularis</i> , New York	+ (OspE and FHBP27)
<i>B. burgdorferi</i> BL224	Lyme disease	Human blood isolate, New York	+ (OspE and FHBP27)

human blood, did not bind hfH. This is contrary to what might be expected for blood isolates. However, it is also important to note that FRO and CON were isolated in 1987 and in the 1960s (specific date unknown), respectively, and have since been passaged extensively in vitro. Exact passage histories for these strains are not known. It is possible that over the course of long-term maintenance in the lab, changes in genome composition (i.e., plasmid loss or genetic rearrangements) that influence the ability of these isolates to bind fH have occurred. Alternatively, this may also reflect natural variation among isolates of a species similar to that reported for the Lyme disease spirochete species, *B. garinii* and *B. afzelii* (1, 9, 11, 12, 16). Hence, intraspecies phenotypic variation among *B. hermsii* isolates is not unexpected.

In this study, *B. burgdorferi* B31MI served as a control in all fH binding assays. *B. burgdorferi* produces multiple FHBP that exhibit different fH binding properties. In an earlier study it

was demonstrated that the OspE protein of the Lyme disease spirochetes is detected by the goat anti-hfH antisera even when hfH is not included in the affinity ligand fH binding assay (13). This is evident in Fig. 1 of this report. Possible explanations for this observation have been discussed in earlier publications from this lab (12, 13). The importance of this control and its bearing on the interpretation of data pertaining to the specificity of binding of fH to *Borrelia* proteins had largely been overlooked in earlier studies (14). In brief, fH is present in high concentrations in the sera of all mammals and by extension is a natural component of the goat anti-hfH antiserum used in the binding analyses described here. The detection of OspE-fH complexes even when exogenous hfH is not added in the assays presumably reflects the ability of OspE to bind to the endogenous goat fH. This complex is then detected by the goat anti-hfH antiserum. Although the goat anti-fH antiserum was generated by using hfH, we and others have shown that it




FIG. 1. Immunoblot affinity ligand binding analysis; identification of human FHBPs in the RFS. Whole-cell lysates of each isolate (indicated above each lane) were generated, fractionated by SDS-PAGE, and immunoblotted. The ability of hfH to bind to the immobilized proteins was tested by the affinity ligand binding immunoblot approach as described in the text with saturating amounts of fH. All bacteria analyzed in panel A were cultivated at 33°C. A negative control in which hfH was not included in the assay is presented.




FIG. 2. Analysis of fH binding using an ELISA format. All methods were as described in the text. Bacteria were cultivated at 33°C, immobilized in the wells of ELISA plates, and incubated with fH (black bars) or without fH (white bars), and fH binding was assessed by using anti-fH antiserum.

recognizes fH from several mammalian species (14). This supports the suggestion that the antiserum recognizes goat fH bound to OspE. The OspE proteins which do not appear to exhibit species specificity with regard to fH binding have been designated as class I FHBPs. In contrast, the class II FHBPs of the Lyme spirochetes exhibit species specificity in their fH binding. These proteins bind hfH but not goat fH (12, 13). The FHBPs of the RFS exhibit binding characteristics that are similar to those of the class II FHBPs of the Lyme disease spirochetes in that they exhibit species specificity in their fH binding properties. The narrower fH binding specificity of the RFS in contrast to that of the Lyme disease spirochetes is consistent with the transmission biology of these bacteria. The RFS remain viable in ticks for several years. This feature enhances the potential for transmission of the spirochetes to mammals. In addition, the RFS can be transovarially transmitted in ticks. In contrast, the Lyme disease spirochetes are not transovarially transmitted and are maintained for relatively shorter periods in ticks. As a consequence, the Lyme spirochetes are highly dependent on the establishment of chronic infection in their mammalian reservoirs, and population maintenance in nature requires that the host range for these bacteria be rather broad. By producing multiple FHBPs that exhibit different binding specificities, the Lyme disease spirochetes can increase their potential host range. In contrast, the biological features of the RFS render them less dependent on mammalian reservoirs in general for population

maintenance in nature. This could account for the more limited set of FHBPs produced by these bacteria.

As a second approach to assess fH binding to the RFS, enzyme-linked immunosorbent assays (ELISAs) were conducted as previously described (12). Equivalent numbers of cells of each isolate analyzed were immobilized in the wells of a 96-well microtiter plate. hfH was added to each well ($10 \text{ ng } \mu\text{l}^{-1}$; 4°C, 15 h), unbound hfH was removed by washing with PBST (PBS with 0.02% Tween 20), goat anti-hfH antiserum was added (1:800, 4 h 4°C), and then horseradish peroxidase-conjugated rabbit anti-goat immunoglobulin G secondary antibody was added (1:40;000, 1 h, 4°C). The one-step Turbo TMB ELISA kit (Pierce) was used for detection, and the plates were read in a Spectromax 400 plate reader. All samples were analyzed in triplicate, and averages and standard deviations are presented (Fig. 2). *B. burgdorferi* B31MI, which has previously been shown to bind fH in an ELISA format, served as the positive control. Immobilized bovine serum albumin served as the negative control. Consistent with the affinity ligand binding analyses, *B. hermsii* MAN and YOR bound fH while *B. anserina* and *B. turicatae* OZ1 did not.

The similarity in the sizes of FHBPs of the RFS and the OspE proteins of the Lyme spirochetes raised the possibility that these proteins are genetically or antigenically related. To assess this possibility, an immunoblot of the RFS isolates was screened with polyclonal anti-OspE antisera (13). Except in the *B. burgdorferi* (positive) controls, immunoreactive proteins




FIG. 3. Constitutive expression of the FHBP of the RFS. Bacteria were cultivated at 25, 33, and 37°C, harvested, and tested for fH binding by the affinity ligand binding immunoblot assay (top) as described in the text. Saturating amounts of fH were employed in the assay. An immunoblot of cell lysates screened with anti-Fla antiserum, which recognizes the constitutively expressed Fla protein, confirmed that the loadings in all lanes were equal (bottom).

were not detected (data not shown). In addition, *ospE*-related sequences were not detected in the RFS by Southern hybridization with PCR-generated *ospE* probes (data not shown). Hence, it can be concluded that FHB19 of the RFS is not an OspE homolog. Based on its lack of homology to OspE and its hfH binding specificity, FHB19 can be classified as a class II FHB19.

The expression of the OspE proteins (class I FHBPs) of the Lyme spirochetes has been demonstrated to increase with temperature (2). To determine if the expression of the FHBPs of the RFS is also influenced by temperature, affinity ligand binding immunoblot assays were performed with bacteria cultivated at 25, 33, or 36°C in Barbour-Stoenner-Kelly-H medium (12% rabbit sera). In these experiments, saturating amounts of hfH were employed (Fig. 3). As a control, the expression level of the constitutively expressed FlaB protein was compared in these bacteria through immunoblot analysis with rabbit anti-FlaB antisera (kindly provided by Michael Theisen). FlaB expression level was unaffected by growth conditions. Similarly, the relative amount of fH binding by the ~19-kDa FHBPs of the RFS did not change with growth condition, indicating constitutive expression. However, a minor increase in expression of an FHB19 of ~28 kDa in *B. parkeri* was observed. The significance of this remains to be determined, as this protein appears to be expressed at a low level. Constitutive expression of most of the FHBPs of the RFS suggests that these proteins are likely to be expressed in ticks. Expression in ticks may serve to protect the spirochetes from the complement ingested by the tick as part of the blood meal.

To assess the biological relevance of fH binding in the

RFS, C3b cleavage assays were performed using a fH binder (*B. hermsii* YOR), a nonbinder (*B. turicatae* OZ1), and a *B. burgdorferi* positive control (BBL224). Cultures of each were pelleted, washed with ice-cold PBS, resuspended in cold RPMI medium (Gibco-BRL), and incubated with 0 or 50 ng of purified hfH (1 h, 37°C). To remove unbound hfH, the cells were washed with PBS. The cells were then resuspended in 15 μ l of PBS, and fI (150 ng; Calbiochem) and C3b (250 ng; Calbiochem) were added. The mixture was incubated for 2 h at 37°C, 15 μ l of SDS-PAGE sample buffer was added, and the samples were fractionated by SDS-PAGE, immunoblotted, and screened with anti-human C3b antiserum (Accurate; 1:800 dilution). Immunoblot methods were as previously described (12). As a positive control for the reaction conditions employed, purified fH (150 ng), fI (150 ng), and C3b (250 ng) were incubated together at 37°C in PBS for 2 h. Efficient cleavage of C3b was observed in the control but not when fH or fI was omitted (negative controls). *B. hermsii* YOR and the positive-control *B. burgdorferi* isolate cleaved C3b, while *B. turicatae* OZ-1 did not, even when threefold more fH (150 ng) was used in the assay (Fig. 4). The fH-fI mediated cleavage of C3b generated the characteristic C3b cleavage products, α' 43 and α' 68. This important observation indicates that surface-bound fH can participate in C3b cleavage and thus may play an important role in immune-system evasion during natural infection in mammals.

In closing, this study presents the first demonstration that some RFS isolates bind fH and cleave C3b. The fH binding specificity of the FHBPs of the RFS is similar to that of the class II FHBPs of the Lyme spirochetes. As discussed above,




FIG. 4. Demonstration of the ability of cell-bound fH to serve as a cofactor for the fI-mediated cleavage of C3b. The cleavage assay was conducted as described in the text, and the reaction products were fractionated by SDS-PAGE using a 15% acrylamide gel. The proteins were transferred to membranes and screened with anti-C3b antiserum.

the *B. turicatae* OZ-1 isolate tested here did not bind fH. It is tempting to speculate that this phenotype may be of relevance to the CNS localization of this species, as has been hypothesized for the potentially neurotropic Lyme disease spirochete species *B. garinii* (12, 13). Unfortunately, additional isolates of *B. turicatae* are not currently available, and therefore it is premature to draw conclusions about the fH binding ability of this species as a whole. Future studies will seek to test the hypothesis that fH binding phenotype influences the pathogenesis and tissue tropism of *Borrelia* species.

REFERENCES

- Alitalo, A., T. Meri, L. Rämö, T. S. Jokiranta, T. Heikkilä, I. J. T. Seppälä, J. Oksi, M. Viljanen, and S. Meri. 2001. Complement evasion by *Borrelia burgdorferi*: serum-resistant strains promote C3b inactivation. *Infect. Immun.* **69**:3685–3691.
- Alitalo, A., M. T. H. Lankinen, I. Seppala, P. Lahdenne, P. S. Hefty, D. Akins, and S. Meri. 2002. Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. *J. Immunol.* **169**:3847–3853.
- Barbour, A. G. 1987. Immunobiology of relapsing fever. *Contrib. Microbiol. Immunol.* **8**:125–137.
- Barbour, A. G., and S. F. Hayes. 1986. Biology of *Borrelia* species. *Microbiol. Rev.* **50**:381–400.
- Barbour, A. G., S. L. Tessier, and H. G. Stoenner. 1982. Variable major proteins of *Borrelia hermsii*. *J. Exp. Med.* **156**:1312–1324.
- Friese, M. A., J. Hellwage, T. S. Jokiranta, S. Meri, H. H. Peter, H. Eibel, and P. F. Zipfel. 1999. FHL-1/reconnectin and factor H: two human complement regulators which are encoded by the same gene are differentially expressed and regulated. *Mol. Immunol.* **36**:809–818.
- Hellwage, J., T. Meri, T. Heikkilä, A. Alitalo, J. Panelius, P. Lahdenne, I. J. T. Seppala, and S. Meri. 2001. The complement regulator factor H binds to the surface protein OspE of *Borrelia burgdorferi*. *J. Biol. Chem.* **276**:8427–8435.
- Kraiczy, P., C. Skerka, M. Kirschfink, V. Brade, and P. F. Zipfel. 2001. Immune evasion of *Borrelia burgdorferi* by acquisition of human complement regulators FHL-1/reconnectin and factor H. *Eur. J. Immunol.* **31**:1674–1684.
- Kraiczy, P., C. Skerka, M. Kirschfink, P. F. Zipfel, and V. Brade. 2001. Mechanism of complement resistance of pathogenic *Borrelia burgdorferi* isolates. *Int. Immunopharmacol.* **1**:3393–3401.

10. **Kraiczky, P., C. Skerka, and P. F. Zipfel.** 2001. Further characterization of complement regulator-acquiring surface proteins of *Borrelia burgdorferi*. *Infect. Immun.* **69**:7800–7809.
11. **Kurtenbach, K., H.-S. Sewell, N. H. Ogden, S. E. Randolph, and P. A. Nuttall.** 1998. Serum complement sensitivity as a key factor in Lyme disease ecology. *Infect. Immun.* **66**:1248–1251.
12. **McDowell, J. V., J. Wolfgang, E. Tran, M. S. Metts, D. Hamilton, and R. T. Marconi.** 2003. Comprehensive analysis of the factor H binding capabilities of *Borrelia* species associated with Lyme disease: delineation of two distinct classes of factor H binding proteins. *Infect. Immun.* **71**:3597–3602.
13. **Metts, S., J. V. McDowell, M. Theisen, P. R. Hansen, and R. T. Marconi.** 2003. Analysis of the OspE determinants involved in the binding of factor H and OspE targeting antibodies elicited during infection in mice. *Infect. Immun.* **71**:3587–3596.
14. **Stevenson, B., N. El-Hage, M. A. Hines, J. C. Miller, and K. Babb.** 2002. Differential binding of host complement inhibitor factor H by *Borrelia burgdorferi* Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. *Infect. Immun.* **70**:491–497.
15. **Stoenner, H. G., T. Dodd, and C. Larsen.** 1982. Antigenic variation of *Borrelia hermsii*. *J. Exp. Med.* **156**:1297–1311.
16. **van Dam, A. P., A. Oei, R. Jaspars, C. Fijen, B. Wilske, L. Spanjaard, and J. Dankert.** 1997. Complement-mediated serum sensitivity among spirochetes that cause Lyme disease. *Infect. Immun.* **65**:1228–1230.